GlaxoSmithKline on Friday earned Food and Drug Administration approval for its shingles vaccine Shingrix.
Here are four things to know.
1. Shingrix is a nonlive, recombinant subunit Shingles vaccine for adults age 50 and older.
2. The vaccine is administered intramuscularly in two doses.
3. In a recent Phase III clinical trial with more than 38,000 patients, Shingrix had a more than 90 percent efficacy against shingles for all age groups.
4. GlaxoSmithKline expects Shingrix to be available shortly, pending a recommendation from the CDC's Advisory Committee on Immunization Practices.
More articles on supply chain:
Analysis: Biosimilar drugs could cut US healthcare spending by $54B
Health apps should be held to high regulatory scrutiny, researchers say
FDA: 50 medical devices at risk of shortages after Hurricane Maria